PPD’s Global Central Lab in Singapore Earns CAP Accreditation

PPD, Inc. (Nasdaq: PPDI) today announced its global central lab operations in Singapore has earned accreditation by the College of American Pathologists (CAP), validating its ability to deliver high-quality, reliable data that meet the highest standard of excellence in enhancing patient safety and speeding drug development.

The Singapore facility is PPD’s fourth central lab to achieve accreditation by the CAP Laboratory Accreditation Program. This internationally recognized program uses rigorous accreditation standards to help laboratories improve patient care by providing quality laboratory services. A multidisciplinary team of practicing lab professionals inspected the facility, examining staff qualifications, laboratory equipment and facilities, safety programs and records, and overall management of laboratory operations.

"Achieving CAP accreditation six weeks after opening our Singapore facility demonstrates the expertise of our scientists and our commitment to excellence,” said Steve Lobel, Ph.D., vice president of PPD’s global central laboratory operations. "Within weeks of opening our laboratory, we added new assay technologies and are supporting high-level testing to expand upon the services we offer our clients.”

PPD opened its Singapore central lab last year in response to growing client demand in Southeast Asia. PPD also operates central labs in Highland Heights, Ky., Beijing, China, and Brussels, Belgium.

PPD is a leading global contract research organization, celebrating 25 years of advancing drug development. We provide discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 40 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the accreditation of PPD’s global central lab in Singapore, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: rapid technological advances that make our products and services less competitive; the ability to attract and retain key personnel; success in sales growth; loss of large contracts; high cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.